p21-Dependent Protective Effects of a Carbon Monoxide–Releasing Molecule-3 in Pulmonary Hypertension

Activation of Lung p53 by Nutlin-3a Prevents and Reverses Experimental Pulmonary Hypertension

(2013) Nathalie Mouraret et al.   CIRCULATION

Antithrombotic Properties of Water-Soluble Carbon Monoxide-Releasing Molecules

(2012) Karol Kramkowski et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

mTORC1 and p53

(2012) Paul Hasty et al.   CELL CYCLE

Interaction of Carbon Monoxide with Transition Metals: Evolutionary Insights into Drug Target Discovery

(2012) Roberta Foresti et al.   CURRENT DRUG TARGETS

Early Macrophage Recruitment and Alternative Activation Are Critical for the Later Development of Hypoxia-Induced Pulmonary Hypertension

(2011) Eleni Vergadi et al.   CIRCULATION

Carbon Monoxide Induced PPARγ SUMOylation and UCP2 Block Inflammatory Gene Expression in Macrophages

(2011) Arvand Haschemi et al.   PLoS One

The therapeutic potential of carbon monoxide

(2010) Roberto Motterlini et al.   NATURE REVIEWS DRUG DISCOVERY

Cellular and Molecular Basis of Pulmonary Arterial Hypertension

(2009) Nicholas W. Morrell et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Water-soluble CO-releasing molecules reduce the development of postoperative ileus via modulation of MAPK/HO-1 signalling and reduction of oxidative stress

(2008) O De Backer et al.   GUT